Journal: Frontiers in Oncology

Article Title: Migration, invasion, and metastasis are mediated by P-Rex1 in neuroblastoma

doi: 10.3389/fonc.2024.1336031

Figure Lengend Snippet: P-Rex1 expression was correlated with and modulated by Rac2 , as opposed to Rac1 or Rac3 . The publicly available Kocak database was accessed to evaluate for associations between expression of P-Rex1 and the three Rac effectors: Rac1 , Rac2 , and Rac3. (A) Whereas Rac1 and Rac3 had statistically significant but relatively weak negative associations with expression of P-Rex1 , Rac2 had a robust, significant, and positive correlation with expression of P-Rex1 . (B) On Rac GTPase assays, the BE(2)-C/shPREX1 cell line did not demonstrate any appreciable decrease in activation of Rac1 or Rac3 protein relative to BE(2)-C/shCON. Neither neuroblastoma cell line produced any total Rac2 protein.

Article Snippet: Anti-Rac3 antibody was purchased from Abcam (Abcam, Cambridge, UK).

Techniques: Expressing, Activation Assay, Produced

Journal: Cancer Cell International

Article Title: Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75

doi: 10.1186/s12935-024-03258-9

Figure Lengend Snippet: 3D structure of RAC3- PIK-75 complex and RAC3- PF-562271 complex based on molecular docking. A The binding mode of the complex RAC3 with PIK-75. B The amino acid residues to which PIK-75 bonded in the protein pocket. C The binding mode of the complex RAC3 with PF-562271. D The amino acid residues to which PF-562271 bonded in the protein pocket

Article Snippet: The primary antibodies used in this study were recombinant anti-RAC3 antibody (1:1000, ab124943, Abcam) and anti-GAPDH antibody (1:5000, ab181602, Abcam) in our study.

Techniques: Binding Assay

Journal: Cancer Cell International

Article Title: Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75

doi: 10.1186/s12935-024-03258-9

Figure Lengend Snippet: RAC3 was higher expressed in GEM-resistant patients. A Representative images of IHC staining of RAC3 of tumor tissue from gemcitabine-sensitive (GEM-sensitive) or gemcitabine-resistant (GEM-resistant) patients. B Western blot analysis of RAC3 in T24 and 5637 after transfected with shNC or shRAC3. C qPCR analysis of the mRNA levels of RAC3 after transfected with shNC or shRAC3. D IC50 analysis of T24 and 5637 treated by gemcitabine. E Western blot analysis of RAC3 after PIK-75- or DMSO-treated. F qPCR analysis of the mRNA levels of RAC3 after PIK-75- or DMSO-treated

Article Snippet: The primary antibodies used in this study were recombinant anti-RAC3 antibody (1:1000, ab124943, Abcam) and anti-GAPDH antibody (1:5000, ab181602, Abcam) in our study.

Techniques: Immunohistochemistry, Western Blot, Transfection